Credit Agreements in the Biotechnology Industry

415 Contracts & Agreements

Browse by Company

AbbVie Inc. (9 contracts)
ACHIEVE LIFE SCIENCES, INC. (3)
ADiTx Therapeutics, Inc. (9)
ADMA BIOLOGICS, INC. (15)
AKCEA THERAPEUTICS, INC. (1)
Akebia Therapeutics, Inc. (2)
Akero Therapeutics, Inc. (2)
Alexion Pharmaceuticals (6)
Alkermes plc. (3)
Alliqua BioMedical, Inc. (5)
ALNYLAM PHARMACEUTICALS, INC. (2)
ALX ONCOLOGY HOLDINGS INC (2)
Amgen Inc. (9)
AMICUS THERAPEUTICS, INC. (2)
AmpliPhi Biosciences Corp (8)
Anika Therapeutics (3)
Aptevo Therapeutics Inc. (6)
ARCA biopharma, Inc. (1)
Arcturus Therapeutics Holdings Inc. (3)
Athenex, Inc. (10)
ATOSSA GENETICS INC (2)
Avid Bioservices, Inc. (2)
Avita Therapeutics, Inc. (2)
AZIYO BIOLOGICS, INC. (7)
AzurRx BioPharma, Inc. (1)
BIOCRYST PHARMACEUTICALS INC (2)
Biogen Inc. (6)
Biohaven Pharmaceutical Holding Co Ltd. (1)
BIOMARIN PHARMACEUTICAL INC (2)
BIOTIME INC (10)
BioXcel Therapeutics, Inc. (5)
C4 Therapeutics, Inc. (2)
CANCER GENETICS, INC (14)
CareDx, Inc. (4)
CATABASIS PHARMACEUTICALS INC (1)
Cellular Biomedicine Group, Inc. (4)
Coherus BioSciences, Inc. (2)
CURIS INC (6)
CYTORI THERAPEUTICS, INC. (1)
Dermira, Inc. (1)
Eagle Pharmaceuticals, Inc. (3)
Emerald Bioscience, Inc. (5)
Emergent BioSolutions Inc. (9)
Epizyme, Inc. (1)
Esperion Therapeutics, Inc. (1)
EXICURE, INC. (4)
Fibrocell Science, Inc. (1)
Flexion Therapeutics Inc (5)
Fortress Biotech, Inc. (7)
GALECTIN THERAPEUTICS INC (5)
Gilead Sciences (3)
Gossamer Bio, Inc. (5)
HALOZYME THERAPEUTICS INC (4)
HARBOR DIVERSIFIED, INC. (7)
HUMANIGEN, INC (2)
iBio, Inc. (11)
IMMUCELL CORP (1)
IMPEL NEUROPHARMA INC (1)
INFINITY PHARMACEUTICALS, INC. (1)
Inmune Bio, Inc. (1)
INOVIO PHARMACEUTICALS, INC. (1)
INSMED Inc (1)
Invitae Corp (4)
IONIS PHARMACEUTICALS INC (1)
IRONWOOD PHARMACEUTICALS INC (5)
Kadmon Holdings, Inc. (8)
Kura Oncology, Inc. (1)
Ligand Pharmaceuticals Incorporated (1)
MANNKIND CORP (4)
MEDICINOVA INC (1)
MeiraGTx Holdings plc (2)
MERRIMACK PHARMACEUTICALS INC (1)
MiMedx Group, Inc. (4)
Molecular Templates, Inc. (3)
Myriad Genetics, Inc. (2)
NANOVIRICIDES, INC. (2)
Natera, Inc. (3)
NEUROCRINE BIOSCIENCES INC (2)
Nuo Therapeutics, Inc. (3)
Opko Health, Inc. (13)
ORAGENICS INC (3)
Organogenesis Holdings Inc. (1)
Orgenesis Inc. (5)
Oyster Point Pharma, Inc. (1)
PDL BIOPHARMA, INC. (10)
Pfenex Inc. (7)
PORTOLA PHARMACEUTICALS INC (2)
PROGENITY, INC. (6)
PTC THERAPEUTICS, INC. (7)
RECURSION PHARMACEUTICALS, INC. (1)
Regeneron Pharmaceuticals (7)
Retrophin, Inc. (6)
Rezolute, Inc. (2)
RIGEL PHARMACEUTICALS INC (4)
Sarepta Therapeutics, Inc. (4)
Seres Therapeutics, Inc. (1)
Sorrento Therapeutics, Inc. (4)
Spectrum Pharmaceuticals, Inc. (2)
Stellar Biotechnologies, Inc. (1)
Synthetic Biologics, Inc. (2)
TG THERAPEUTICS, INC. (3)
United Therapeutics Corp (5)
VBI Vaccines Inc (6)
VERACYTE, INC. (1)
Verastem, Inc. (1)
Vertex Pharmaceuticals Inc (4)
WINDTREE THERAPEUTICS INC (2)
Zai Lab Ltd (2)

Recent Contracts

Credit Agreement, dated as of December 13, 2024, by and among Esperion Therapeutics, Inc., GLAS USA LLC, as administrative agent, and the lenders party thereto (Esperion Therapeutics, Inc., Filed With SEC on December 13, 2024)
Form of Third Amended and Restated Registration Rights Agreement, among the Company and Oaktree-TCDRS Strategic Credit, LLC, Oaktree-Forrest Multi-Strategy, LLC, Oaktree-TBMR... (BioXcel Therapeutics, Inc., Filed With SEC on November 21, 2024)
Third Amendment to Secured Convertible Credit and Security Agreement, dated as of November 12, 2024, by and among the Issuer, Innoviva Sub and the other parties thereto (AmpliPhi Biosciences Corp, Filed With SEC on November 15, 2024)
Second Amendment to Credit and Security Agreement, dated as of November 12, 2024, by and among the Issuer, Innoviva Sub and the other parties thereto (AmpliPhi Biosciences Corp, Filed With SEC on November 15, 2024)
Supplemental Line of Credit Agreement, dated as of November 14, 2024, by and between Richard E. Uihlein and the Company (GALECTIN THERAPEUTICS INC, Filed With SEC on November 14, 2024)
Third Amendment to Credit Agreement dated as of November 12, 2024 by and among the Company, the lenders named therein and the administrative agent (Organogenesis Holdings Inc., Filed With SEC on November 13, 2024)
Credit Agreement entered into by and among Fortress Biotech, Inc., the lenders from time to time party thereto, and Oaktree Fund Administration, LLC on July 25, 2024 (Fortress Biotech, Inc., Filed With SEC on September 27, 2024)
Amendment to Line of Credit Agreement dated (NANOVIRICIDES, INC., Filed With SEC on September 27, 2024)
Credit Agreement, dated as of August 30, 2024, by and among Emergent BioSolutions Inc., the lenders from time to time party thereto and OHA Agency LLC, as administrative agent (Emergent BioSolutions Inc., Filed With SEC on September 3, 2024)
Credit Agreement, dated as of August 12, 2024, among Biogen Inc., Bank of America, N.A., as administrative agent, swing line lender and the L/C issuer, and the other lenders party... (Biogen Inc., Filed With SEC on August 14, 2024)
First Amendment to Credit Agreement, dated as of July 8, 2024, among Ligand Pharmaceuticals Incorporated, certain of its subsidiaries, as Guarantors, the Lenders, and Citibank,... (Ligand Pharmaceuticals Incorporated, Filed With SEC on August 7, 2024)
First Amendment to Credit Agreement and First Amendment to Revolving Line of Credit, dated June 26, 2024, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National... (Arcturus Therapeutics Holdings Inc., Filed With SEC on August 5, 2024)
First Amendment to Credit Agreement, dated June 20, 2024, by and between Vertex Pharmaceuticals Incorporated and Bank of America N.A (Vertex Pharmaceuticals Inc, Filed With SEC on August 2, 2024)
Unofficial English Translation of Credit Agreement, dated as of July 5, 2024, by and between Zai Lab (Shanghai) Co., Ltd. and China Merchants Bank Co., Ltd., Shanghai Branch (Zai Lab Ltd, Filed With SEC on July 9, 2024)
Extension of Credit, dated May 29, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC (CYTORI THERAPEUTICS, INC., Filed With SEC on June 4, 2024)
Tenth Amendment to Credit Agreement dated May 14, 2024, between iBio CDMO LLC and Woodforest National Bank (iBio, Inc., Filed With SEC on May 20, 2024)
Warrant agreement, dated March 12, 2024 by and between the Registrant and Hercules Private Credit Fund 1 L.P (Akero Therapeutics, Inc., Filed With SEC on May 10, 2024)
Fourth Amendment to the Credit and Security Agreement with MidCap Financial Trust, dated April 11, 2024 (RIGEL PHARMACEUTICALS INC, Filed With SEC on May 7, 2024)
Second Amendment to Credit Agreement, dated March 27, 2024, by and among Elutia Inc., SWK Funding LLC, as Agent, and the Lenders from time to time party thereto (AZIYO BIOLOGICS, INC., Filed With SEC on April 1, 2024)
Ninth Amendment to Credit Agreement dated March 28, 2024, between iBio CDMO LLC and Woodforest National Bank (iBio, Inc., Filed With SEC on April 1, 2024)
Fourth Amendment to Credit Agreement and Guaranty, dated March 20, 2024, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower,... (BioXcel Therapeutics, Inc., Filed With SEC on March 22, 2024)
Warrant Agreement, by and between Akero Therapeutics, Inc. and Hercules Private Credit Fund 1 L.P., dated March 12, 2024 (Akero Therapeutics, Inc., Filed With SEC on March 18, 2024)
Consent and Amendment to Amended and Restated Notes Purchase Agreement and Guaranty, dated December 20, 2023, by and among MeiraGTx Holdings plc, as issuer, the subsidiary... (MeiraGTx Holdings plc, Filed With SEC on March 15, 2024)
Amendment No. 2 to Credit Agreement, dated as of March 12, 2024, by and among the Company, the lenders party thereto and Bank of America, N.A. as administrative Agent (Avid Bioservices, Inc., Filed With SEC on March 14, 2024)
Amended Credit Agreement, dated as of October 3, 2022 and amended on September 6, 2023 and March 13, 2024, by and between the Company and Mattress Liquidators, Inc (AzurRx BioPharma, Inc., Filed With SEC on March 14, 2024)
Second Amendment to Convertible Credit and Security Agreement (AmpliPhi Biosciences Corp, Filed With SEC on March 4, 2024)
First Amendment to Credit and Security Agreement (AmpliPhi Biosciences Corp, Filed With SEC on March 4, 2024)
Credit and Security Agreement, dated March 4, 2024 (AmpliPhi Biosciences Corp, Filed With SEC on March 4, 2024)
Second Amendment to Third Amended and Restated Credit Agreement, among Eagle Pharmaceuticals, Inc., as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the... (Eagle Pharmaceuticals, Inc., Filed With SEC on March 1, 2024)
Allonge to and Amendment of Line of Credit between the Company and Gorham Savings Bank, dated February 22, 2024 (IMMUCELL CORP, Filed With SEC on February 27, 2024)
Waiver and First Amendment to Orbimed Credit Agreement (Avita Therapeutics, Inc., Filed With SEC on February 22, 2024)
Line of Credit Agreement between the Company and Dr. Anil R. Diwan, dated November 13, 2023 (NANOVIRICIDES, INC., Filed With SEC on February 16, 2024)
Third Amendment to Credit Agreement and Guaranty dated February 12, 2024, which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the... (BioXcel Therapeutics, Inc., Filed With SEC on February 12, 2024)
Unofficial English Translation of Maximum Credit Contract, dated as of February (Zai Lab Ltd, Filed With SEC on February 8, 2024)
Schedule to Credit and Security Agreement, dated January 16, 2024, by and between iBio, Inc. and Loeb Term Solutions LLC (iBio, Inc., Filed With SEC on January 19, 2024)
Credit and Security Agreement, dated January 16, 2024, by and between iBio, Inc. and Loeb Term Solutions LLC (iBio, Inc., Filed With SEC on January 19, 2024)
Limited Waiver and First Amendment to Third Amended and Restated Credit Agreement, among Eagle Pharmaceuticals, Inc., as borrower, JPMorgan Chase Bank, N.A., as administrative... (Eagle Pharmaceuticals, Inc., Filed With SEC on January 16, 2024)
Eighth Amendment to Credit Agreement dated December 22, 2023 between iBio CDMO LLC and Woodforest National Bank (iBio, Inc., Filed With SEC on December 26, 2023)
Amended and Restated Registration Rights Agreement, dated December 5, 2023, among the Company and Oaktree-TCDRS Strategic Credit, LLC, Oaktree-Forrest Multi-Strategy, LLC,... (BioXcel Therapeutics, Inc., Filed With SEC on December 6, 2023)
Waiver and First Amendment to Credit Agreement and Guaranty, by and between the Company, the lenders party thereto and Oaktree Fund Administration LLC dated November 13, 2023 (BioXcel Therapeutics, Inc., Filed With SEC on November 14, 2023)